Rep. Carol Devine Miller discloses trade(s) in PFE, DGX, TGT, USB
Carol Devine Miller (WV01) disclosed 4 transactions, traded Mar 10: 0 purchases and 4 sales.
| Traded | Ticker | Company | Action | Amount | Owner |
|---|---|---|---|---|---|
| Mar 10 | PFE | Pfizer, Inc. | Sell | $15,001 - $50,000 | Spouse |
| Mar 10 | DGX | Quest Diagnostics Incorporated | Sell | $15,001 - $50,000 | Spouse |
| Mar 10 | TGT | Target Corporation | Sell | $15,001 - $50,000 | Spouse |
| Mar 10 | USB | U.S. Bancorp | Sell | $15,001 - $50,000 | Spouse |
ORIGINAL FILING ↗ALL FILINGS BY CAROL DEVINE MILLER →CONGRESS TRADES DASHBOARD →
Amounts are the ranges members report. Rows are read automatically from the filing; a trade split across a page break can be missed, so the original filing is the full record.
What This Means
A U.S. representative has filed financial disclosures covering equity transactions in four publicly traded companies spanning pharmaceuticals, healthcare services, retail, and banking. Congressional stock trading disclosures are routine filings required by law and tracked by markets observers and governance advocates as part of broader monitoring of insider trading risk and potential conflicts of interest among lawmakers.
Sources (1)
Every claim below links directly to the original reporting it was drawn from. Penblock synthesizes and cross-references these sources — it doesn't originate the reporting.
- Carol Devine MillerSep 30, 2026View the original filing at the House Clerk ↗
How This Could Play Out
First assessed Sep 30
Resolved
LIKELYNo material market impact; routine disclosure filings are processed as standard governance compliance with no new information about the underlying companies or legislative intent.
Status quo
LIKELYThese transactions remain a minor data point in broader congressional trading surveillance, with minimal direct effect on sector or individual stock valuations absent additional context about legislative action or conflict-of-interest concerns.
Worsens
UNLIKELYIf the timing or pattern of these sales were to trigger formal insider-trading investigations or prompt legislative scrutiny of healthcare/financial sector regulation, it could create reputational pressure on the affected companies and heighten governance risk premiums in those sectors.
SPONSORED
More on Congressional Stock Trading
- Rep. James A. Himes files a Periodic Transaction ReportOct 20
- Rep. Jonathan Jackson discloses trade(s) in DDOG, EL, GH, TYG, VSATOct 19
- Rep. Michael Rulli discloses trade(s) in GOOG, WSBCOct 19
- Attorneys for Ilhan Omar seek return of items taken during home searchOct 17
- Rep. Laurel Lee discloses trade(s) in BAC, NOKBFOct 16
- Rep. Scott H. Peters files a Periodic Transaction ReportOct 15
Get the market digest by email
One email each morning: yesterday's key story and what it means for markets. Free.